Cite this: *Med. Chem. Commun.*, 2017, 8, 1850

4-Hydroxy-*N*-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide: a novel inhibitor of the canonical NF- κ B cascade†

Agnese C. Pippione, ^a Antonella Federico, ^a Alex Ducime, ^a Stefano Sainas, ^a Donatella Boschi, ^a Alessandro Barge, ^a Elisa Lupino, ^b Marco Piccinini, ^b Michael Kubbutat, ^c Jean-Marie Contreras, ^d Christophe Morice, ^d Salam Al-Karadaghi ^e and Marco L. Lolli ^{*a}

Received 30th May 2017,
Accepted 22nd August 2017

DOI: 10.1039/c7md00278e

rsc.li/medchemcomm

The NF- κ B signaling pathway is a validated oncological target. Here, we applied scaffold hopping to IMD-0354, a presumed IKK β inhibitor, and identified 4-hydroxy-*N*-[3,5-bis(trifluoromethyl)phenyl]-1,2,5-thiadiazole-3-carboxamide (**4**) as a nM-inhibitor of the NF- κ B pathway. However, both **4** and IMD-0354, being potent inhibitors of the canonical NF- κ B pathway, were found to be inactive in human IKK β enzyme assays.

NF- κ B is a ubiquitously expressed family of transcription factors, known to be key regulators of immune response, cell proliferation, cell death and inflammation.¹ NF- κ B dimers are normally inhibited in the cytoplasm of resting cells by proteins called I κ B. Following cell stimulation, the inhibitory I κ B proteins are rapidly phosphorylated by the so-called IKK kinases, and subsequently degraded by the 26S proteasome. This is followed by the translocation of the transcription factors to the nuclei and subsequent activation of the corresponding gene expression (the so-called canonical pathway of NF- κ B activation). NF- κ B signaling has been found to be constitutively activated in a variety of malignancies, leading to uncontrolled apoptosis, cell cycle deregulation and metastatic growth.¹ These observations validated the NF- κ B pathway as an oncologic target, in particular in breast² and thyroid cancer.³ The trimeric IKK complex involved in the activation of the canonical NF- κ B pathway contains two catalytic subunits, IKK α and IKK β kinase, and a regulatory protein IKK γ (also called NEMO). In a parallel, so-called non-canonical pathway,⁴ TNF-receptor superfamily members selectively activate a different set of kinases, NF- κ B-inducing kinase (NIK) and I κ B kinase 1 (IKK1).⁴

The efforts aimed at discovering new NF- κ B inhibitors, and particularly inhibitors of IKK β , have been intensified in recent years.⁵ Recently, the X-ray structures of IKK β in a ligand-free form and in complex with an inhibitor have been reported,^{6,7} thus providing new opportunities for the design of new potent inhibitors.¹ Although no IKK β inhibitors have reached the human pharmacopoeia yet, some interesting molecules have been studied. Among those is PS-1145 (Fig. 1), a β -carboline analogue known to potently and selectively inhibit the endogenous IKK complex with an IC₅₀ of 150 nM.^{8–10} Other examples include, BMS-345541¹¹ which acts by allosterically inhibiting IKK β , and IMD-0354, which reached the stage of clinical trials¹² (Fig. 1). IMD-0354 was designed by the *Institute of Medicinal Molecular Design Inc* (Tokyo, Japan) and is claimed to be a selective inhibitor of IKK β .¹³ The compound has completed phase 1 clinical trials as an anti-inflammatory, anti-allergic and anti-microbial agent,¹⁴ while its prodrug, called IMD-1041¹⁵ was evaluated in clinical trials that are currently awaiting proof-of-concept results (NCT00883584).¹⁴

The biological activity of IMD-0354 has been described in a variety of assays related to metabolic diseases and cardiovascular diseases.^{15–27} In particular, it has been reported that

^a Department of Science and Drug Technology, University of Torino, via Pietro Giuria 9, 10125 Torino, Italy

^b Department of Oncology, University of Torino, via Michelangelo 27/B, 10126 Torino, Italy

^c ProQinase GmbH, Breisacher Str. 117, 79106 Freiburg, Germany

^d Prestwick Chemical, 220 Boulevard Gonthier d'Andernach, 67400 Illkirch, France

^e SARomics Biostructures and Department of Biochemistry & Structural Biology, Lund University, Lund, Sweden

† Electronic supplementary information (ESI) available: Additional biochemical data, chemistry, NMR characterization of final compounds, biochemical protocols. See DOI: 10.1039/c7md00278e

Fig. 1 PS-1145, BMS-345541 and IMD-0354 as examples of IKK β inhibitors.

IMD-0354 is able to suppress neoplastic proliferation of human mast cells with constitutively activated c-kit receptor,²⁸ and inhibits the growth of human breast cancer cells MDA-MB-231, HMC1-8 and MCF-7.²⁹

Bio(iso)steric replacement is a widely used approach in medicinal chemistry, aimed at improving the characteristics of a lead compound, such as bioavailability, selectivity, and potency.³⁰ As an example of the use of the method, we recently designed a new generation of potent hDHODH inhibitors³¹ using hydroxylated azoles. In these systems, the substitution of the azole ring allowed fine-tuning of the accessible chemical space,³² thus increasing the probability of triggering the desired change in biological activity. Here, we applied a similar approach to the phenolic substructure in IMD-0354 to design new IKK β inhibitors. The compounds 1 to 11 (Fig. 2) have been designed using four different acidic azoles: *hydroxyoxadiazole*, *hydroxythiadiazole*, *hydroxytriazole* and *hydroxypyrazole*. The four hydroxyazole systems have been selected to bioisosterically modulate the phenolic moiety of IMD-0354 by their different acidic and lipophilic properties.³³ Notably, *hydroxytriazole* and *hydroxypyrazole* scaffolds can be modified by the addition of protruding substituents, which may be designed to occupy the surrounding chemical space in several directions. Schemes 1 and 2 outline the synthetic methodologies used for the preparation of the target compounds 1–11.

In some cases, a benzyloxy-protected azolecarboxylate (12, 16, 20) was transformed into the corresponding acyl chloride, which was allowed to react with the appropriate aniline, thus obtaining the corresponding amide (compounds 13, 17 and 21). The removal of the protecting benzyl group was accomplished by applying room pressure hydrogenation conditions (1, 2, 7, 8, 10, 11). In the case of triazole analogue 9 (Scheme 2), the coupling reaction was conducted on the *p*-methoxybenzyl protected precursor 18, previously obtained

Scheme 1 Synthesis of 1,2,5-oxadiazole and thiadiazole analogues 1–6: i) a) oxalyl chloride, DMF, dry THF, b) substituted aniline, dry pyridine, dry THF; ii) H₂, Pd/C, dry THF; iii) CH₃I, Cs₂CO₃, dry THF; iv) HBTU, DMAP, 3,5-bis(trifluoromethyl)aniline, dry DMF.

from its corresponding ethyl ester.³³ The resulting amide 19 was then deprotected under acidic conditions (TFA).

Other compounds (4, 5 and 3, Scheme 1) were obtained by coupling unprotected 4-hydroxythiadiazole-3-carboxylic acyl chloride of the corresponding acid 14³⁴ or commercial available 4-aminofurazan-3-carboxylic acid 15 with the corresponding aniline. Compound 4 was then methylated with methyl iodide to obtain compound 6. Synthetic procedures and spectral characterization of the final compounds 1–11 are shown in the ESI.[†]

The designed compounds 1–11 (Fig. 2) were evaluated both by enzymatic and cellular assays and compared to IMD-0354³⁵ and PS-1145,³⁶ the latter used as IKK β reference inhibitor⁸ (Table 1).

Fig. 2 The bioisosteric scaffold hopping strategy applied to IMD-0354 using *hydroxyoxadiazole*, *hydroxythiadiazole*, *hydroxytriazole* and *hydroxypyrazole* scaffolds.

Scheme 2 Synthesis of triazole and pyrazole analogues (7–11). i) a) Oxalyl chloride, DMF, dry THF; b) 3,5-bis(trifluoromethyl)aniline, dry pyridine, dry THF; ii) H₂, Pd/C, dry THF; iii) TFA, 45 °C.

Table 1 The effects of IMD-0354, PS-1145 and the designed compounds on: ATP-based kinase assays for IKK β , IKK α , IKK ϵ and NIK (expressed as IC₅₀ value, μ M); I κ B α degradation assay in Jurkat cells (expressed as IC₅₀ value, μ M). All experiments were performed in triplicate, and data represent means $\pm$ standard deviation (SD)

Compound	IKK β IC ₅₀ $\pm$ SD ^a (μ M) (% inhib at 100 μ M)	IKK α IC ₅₀ $\pm$ SD ^a (μ M) (% inhib at 100 μ M)	IKK ϵ IC ₅₀ $\pm$ SD ^a (μ M) (% inhib at 100 μ M)	NIK IC ₅₀ $\pm$ SD ^a (μ M) (% inhib at 100 μ M)	IC ₅₀ (μ M) on I κ B α degradation assay ^b
IMD-0354	>100 (5.43)	>100 (3.45)	>100 (30.5)	>100 (13.8)	0.218 $\pm$ 0.007
PS-1145	0.087 $\pm$ 0.005	>100	>100	>100	0.186 $\pm$ 0.008
1	>100 (12.2)	>100 (18.6)	58.5 $\pm$ 0.4	>100 (19.3)	6.93 $\pm$ 0.12
2	>100 (2.06)	>100 (−2.5)	>100 (32.1)	>100 (11.8)	1.72 $\pm$ 0.11
3	>100 (31.6)	>100 (29.3)	44.8 $\pm$ 0.8	>100 (−9.20)	>100
4	>100 (−10.3)	>100 (25.2)	>100 (30.2)	>100 (4.34)	0.143 $\pm$ 0.005
5	>100 (−0.94)	35.5 $\pm$ 0.6	>100 (25.8)	>100 (−1.1)	>100
6	>100 (8.51)	>100 (24.1)	>100 (21.9)	>100 (−1.9)	>100
7	>100 (5.19)	>100 (46.9)	>100 (6.92)	>100 (9.1)	>100
8	>100 (11.2)	>100 (13.1)	58.5 $\pm$ 0.3	>100 (12.1)	>100
9	>100 (5.14)	>100 (24.5)	>100 (15.3)	>100 (−9.5)	>100
10	>100 (12.7)	>100 (12.1)	>100 (17.2)	>100 (7.23)	25.9 $\pm$ 0.4
11	>100 (13.9)	>100 (13.2)	>100 (14.2)	>100 (24.1)	1.32 $\pm$ 0.21

^a ATP-based kinase assays for IKK β , IKK α , IKK ϵ and NIK (expressed as IC₅₀ value, μ M). ^b I κ B α degradation assay in Jurkat cells (expressed as IC₅₀ value, μ M).

At the enzymatic level, the activity was assessed on recombinant human IKK β . Surprisingly, the IMD-0354 *lead*, as well as the designed compounds 1–11, were found to be inactive in the assays (Table 1). This result does not agree with the earlier proposed mechanism of action of IMD-0354, which assumes that the compound is a potent inhibitor of IKK β .^{28,29,37} In particular, its molecular structure was originally designed by analysing the binding mode of *aspirin* to IKK β at the APB IKK-2 binding site,²⁸ and based on that it was suggested to compete with ATP for binding to IKK β .³⁸ Based on an NF- κ B-IKK β reporter assay that uses a constitutively active IKK β mutant,¹⁷ the compound's mechanism of action was suggested to involve the inhibition of phosphorylation of I κ B.

Indeed, IMD-0354 was found to inhibit the activated expression of NF- κ B in a dose-dependent manner in HepG2 cells transfected with pFLAG-CMV-IKK β (S177E/S181E) vector, and subsequent verification of I κ B α degradation by Western blot analysis of cytosolic phospho-I κ B α . The authors concluded¹⁷ that the results were consistent with IKK β inhibition although IMD-0354 was not assayed on isolated enzyme. In recent years, Azucena Gomez-Cabrero *et al.*³⁹ defined IMD-0354 as “an indirect inhibitor of NF- κ B”, probably due to the lack of strong evidence supporting an IKK β related mechanism. In order to get a broader overview of the action of IMD-0354, we assayed both IMD-0354 and PS-1145, as well as compounds 1–11, against the other three kinases involved in the *canonical* and *non-canonical* NF- κ B activation pathways (IKK α , IKK ϵ and NIK). In this assay the newly synthesized compounds and IMD-0354 were found to be essentially inactive (only modest activity of compounds 1, 3 and 5 in the μ M range was observed, Table 1).

Since IMD-0354 has been described as potent inhibitor of the NF- κ B pathway in cellular assays, we also evaluated the ability of IMD-0354 and compounds 1–11 to block the NF- κ B pathway. In these experiments the capacity of the compounds

to inhibit the degradation of I κ B α after inflammatory stimulus was evaluated in Jurkat cells. In agreement with earlier results,¹⁷ these assays showed IMD-0354 to be a potent NF- κ B inhibitor with IC₅₀ = 0.218 μ M (Table 1 and Fig. 3). Among the new compounds, the hydroxythiadiazole 4 was the most active, with IC₅₀ of 0.143 μ M (Table 1 and Fig. 3). Compounds 1, 2, 10 and 11 were active in the low μ M range.

The effects of PS-1145, IMD-0354 and compound 4 on NF- κ B gene reporter assay in Jurkat (TIB-152, ATCC) and MDA-MB-231 (ACC-732, DSMZ) cells were also evaluated (Fig. 4).

All three compounds were found active on TNF α -activated Jurkat cells 6 h post-treatment, with compound 4 having higher potency than IMD-0354 and PS-1145 (residual activity at 1 μ M: IMD-0354, 23.48%; PS-1145, 38.14%; 4, 15.91%). However, both compounds 4 and IMD-0354 were almost completely inactive on MDA-MB-231 cells 6 h post-treatment (residual activity at 10 μ M: IMD-0354, 98.99%; compound 4, 96.08%) and showed an appreciable activity 24 h post-treatment (residual activity at 10 μ M: IMD-0354, 58.27%; compound 4, 63.01%). Conversely, 10 μ M PS-1145 showed potent activity not only at 24 h but also at 6 h (residual activity at 10 μ M: 19.52% (6 h) and 8.67% (24 h)). The different inhibitory activity showed of IMD-0354 and compound 4 in gene reporter assay, carried-out in Jurkat and MDA-MB-231

Table 2 Antiproliferative and cytotoxic effects of compound 4, IMD-0354 and PS-1145 on MDA-MB-231 cells. Cells were exposed to inhibitors for 72 h. Data obtained for IMD-0354 agree with previously reported results.²⁹ Data obtained for PS-1145 agree with previously reported antiproliferation assays in MDA-MB-231 cells.⁴⁰ Values are means $\pm$ SD of three independent experiments

Compound	Antiproliferative effect IC ₅₀ $\pm$ SD (μ M)	Cytotoxicity IC ₅₀ $\pm$ SD (μ M)
4	1.29 $\pm$ 0.08	53 $\pm$ 2
IMD-0354	0.64 $\pm$ 0.04	0.85 $\pm$ 0.01
PS-1145	0.90 $\pm$ 0.07	>100

Fig. 3 Effects of compound 4 on IκBα degradation in Jurkat cells stimulated by TNF-α. IκBα protein expression was evaluated by immunoblotting. One representative immunoblot of three independent experiments is shown. Graphs represent IκBα relative band intensity quantified by densitometric analysis after normalization using β-actin as reference. Values are means ± SD of three independent experiments.

Fig. 4 Effects of PS-1145, IMD-0354 and compound 4 on NF-κB gene reporter assay in Jurkat and MDA-MB-231 cells.

cells, is probably a consequence of the activation status of the NF-κB pathway. In fact, in Jurkat cells the NF-κB pathway was activated through the treatment with TNFα whilst in MDA-MB-231 cells the NF-κB signaling pathway was reported to be constitutively activated and driven by both IKKβ and IKKα.⁴⁰

The anti-inflammatory effects of compound 4 were evaluated in LPS-stimulated THP-1 (ACC-16, DSMZ) in which the canonical NF-κB signaling pathway controls the expression of

several pro-inflammatory cytokines.⁴¹ Compound 4 prevented in a dose-dependent manner the LPS-induced degradation of IκBα (Fig. 5).

These results also agree with earlier experiments, which showed that IMD-0354 is able to specifically block the NF-κB pathway when induced by proinflammatory cytokines, such as TNFα and IL-1β.^{15,29} The presented experiments show that compound 4 potently blocks the NF-κB cascade, particularly in conditions of TNFα activation. However, similarly to IMD-0354, compound 4 does not inhibit IKKβ at enzymatic level (Table 1).

For a better understanding of the possible role of IKKβ in the IMD-0354 mechanism of action, we assayed the compound against the trimeric IKKβ-IKKα-Nemo complex, isolated from Jurkat cells treated with TNFα. In this assay, IMD-0354 showed only weak activity (40% inhibition at 100 μM, see ESI†), which does not explain the claimed potency of the compound on the NF-κB cascade. Moreover, in Jurkat cells exposed to IMD-0354 and treated with TNFα, the IKKs of the trimeric complex were found to be phosphorylated (ESI†), indicating that the TNFα stimulus did reach them. These results suggest that the mechanism of inhibition of the canonical NF-κB pathway by IMD-0354 is probably more complex than it was thought. However, the elucidation of this mechanism is outside the scope of this publication.

Finally, we also studied antiproliferative activity and cytotoxicity of compounds 4 on MDA-MB-231 cells, comparing them to IMD-0354 and PS-1145 (Table 2). Quantitation of DNA content and a fluorescent assay to assess cell membrane integrity were used to evaluate cell proliferation and cytotoxicity, respectively.

It can be seen from the data in Table 2 that compound 4 has antiproliferative effect in the low μM range (1.29 μM), slightly lower than that of the two lead compounds. On the other hand, this compound is not cytotoxic as IMD-0354, showing an effect more reminiscent of that of PS-1145, able to block the NF-κB cascade without significant cytotoxicity. In contrast to compound 4 and PS-1145, IMD-0354 has similar IC₅₀ in both proliferation and cytotoxicity assays.

In conclusion, here we introduce the hydroxythiadiazole 4 as a nanomolar inhibitor of the canonical NF-κB cascade. The compound was designed through a bioisosteric scaffold hopping approach applied to the phenolic moiety of IMD-0354. When compared to IMD-0354, compound 4 showed

Fig. 5 Effects of compound 4, IMD-0354, PS-1145, aspirin (ASA) and indomethacin (Indo) on IκBα degradation in THP-1 cells stimulated by LPS. IκBα protein expression was evaluated by immunoblotting. One representative immunoblot of three independent experiments is shown.

similar mode of action, although with higher potency in blocking the NF- κ B cascade on Jurkat cells and lower cytotoxicity on MDA-MB-231 cells. Both 4 and the lead IMD-0354 were found to be inactive in IKK β enzymatic assays, although both being able to inhibit the canonical NF- κ B pathway after TNF α or LPS stimulus.

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgements

This research was financially supported by the TAKTIC *Translational Kinase Tumour Inhibitor discovery Consortium* FP7-SME-2012 grant 315746. Authors wish to thank Dr. Livio Stevanato for performing all the NMR experiments and for maintenance of the instrument.

Notes and references

- H. Park, Y. Shin, H. Choe and S. Hong, *J. Am. Chem. Soc.*, 2015, **137**, 337–348.
- W. Wang, S. A. Nag and R. Zhang, *Curr. Med. Chem.*, 2015, **22**, 264–289.
- N. Pozdeyev, A. Berlinberg, K. Wuensch, W. M. Wood, Q. Zhou, H. Shibata and B. R. Haugen, *PLoS One*, 2015, **10**, e0134901.
- S.-C. Sun, *Cell Res.*, 2011, **21**, 71–85.
- S. K. Arepalli, M. Choi, J. K. Jung and H. Lee, *Expert Opin. Ther. Pat.*, 2015, **25**, 319–334.
- G. Xu, Y. Lo, Q. Li, G. Napolitano, X. Wu, X. Jiang, M. Dreano, M. Karin and H. Wu, *Nature*, 2011, **472**, 325.
- S. Liu, Y. R. Misquitta, A. Olland, M. A. Johnson, K. S. Kelleher, R. Kriz, L. L. Lin, M. Stahl and L. Mosyak, *J. Biol. Chem.*, 2013, **288**, 22758.
- A. C. Castro, L. C. Dang, F. Soucy, L. Grenier, H. Mazdiyasni, M. Hottelet, L. Parent, C. Pien, V. Palombella and J. Adams, *Bioorg. Med. Chem. Lett.*, 2003, **13**, 2419–2422.
- A. Yemelyanov, A. Gasparian, P. Lindholm, L. Dang, J. W. Pierce, F. Kisseljov, A. Karseladze and I. Budunova, *Oncogene*, 2006, **25**, 387–398.
- T. Hideshima, D. Chauhan, P. Richardson, C. Mitsiades, N. Mitsiades, T. Hayashi, N. Munshi, L. Dang, A. Castro, V. Palombella, J. Adams and K. C. Anderson, *J. Biol. Chem.*, 2002, **277**, 16639–16647.
- C. Gamble, K. McIntosh, R. Scott, K. H. Ho, R. Plevin and A. Paul, *Br. J. Pharmacol.*, 2012, **165**, 802–819.
- J.-J. Huang, H.-X. Chu, Z.-Y. Jiang, X.-J. Zhang, H.-P. Sun and Q.-D. You, *Curr. Med. Chem.*, 2014, **21**, 3893–3917.
- P. D. Coish, P. L. Wickens and T. B. Lowinger, *Expert Opin. Ther. Pat.*, 2006, **16**, 1–12.
- <http://www.immd.co.jp/en/development.html> - pipeline.
- A. Lennikov, N. Kitaichi, K. Noda, R. Ando, Z. Dong, J. Fukuhara, S. Kinoshita, K. Namba, M. Mizutani, T. Fujikawa, A. Itai, S. Ohno and S. Ishida, *Mol. Vision*, 2012, **18**, 2586–2597.
- A. Sugita, H. Ogawa, M. Azuma, S. Muto, A. Honjo, H. Yanagawa, Y. Nishioka, K. Tani, A. Itai and S. Sone, *Int. Arch. Allergy Immunol.*, 2009, **148**, 186–198.
- Y. Onai, J.-i. Suzuki, T. Kakuta, Y. Maejima, G. Haraguchi, H. Fukasawa, S. Muto, A. Itai and M. Isobe, *Cardiovasc. Res.*, 2004, **63**, 51–59.
- R. Watanabe, R. W. Azuma, J.-i. Suzuki, M. Ogawa, A. Itai, Y. Hirata, I. Komuro and M. Isobe, *Am. J. Physiol.*, 2013, **305**, H1761–H1771.
- Y. Onai, J.-i. Suzuki, Y. Maejima, G. Haraguchi, S. Muto, A. Itai and M. Isobe, *Am. J. Physiol.*, 2007, **292**, H530–H538.
- H. Ogawa, M. Azuma, S. Muto, Y. Nishioka, A. Honjo, T. Tezuka, H. Uehara, K. Izumi, A. Itai and S. Sone, *Clin. Exp. Allergy*, 2011, **41**, 104–115.
- J. Wei, M. Shi, W.-Q. Wu, H. Xu, T. Wang, N. Wang, J.-L. Ma and Y.-G. Wang, *World J. Gastroenterol.*, 2011, **17**, 5203–5213.
- Y. Nishioka, *Kokyu*, 2007, **26**, 92–107.
- J. Kamon, T. Yamauchi, S. Muto, S. Takekawa, Y. Ito, Y. Hada, W. Ogawa, A. Itai, M. Kasuga, K. Tobe and T. Kadowaki, *Biochem. Biophys. Res. Commun.*, 2004, **323**, 242–248.
- M. Inayama, Y. Nishioka, M. Azuma, S. Muto, Y. Aono, H. Makino, K. Tani, H. Uehara, K. Izumi, A. Itai and S. Sone, *Am. J. Respir. Crit. Care Med.*, 2006, **173**, 1016–1022.
- A. Tanaka and H. Matsuda, *Ensho to Men'eki*, 2007, **15**, 676–680.
- S. Hosokawa, G. Haraguchi, A. Sasaki, H. Arai, S. Muto, A. Itai, S. Doi, S. Mizutani and M. Isobe, *Cardiovasc. Res.*, 2013, **99**, 35–43.
- A. Tanaka, S. Muto, K. Jung, A. Itai and H. Matsuda, *J. Invest. Dermatol.*, 2007, **127**, 855–863.
- A. Tanaka, M. Konno, S. Muto, N. Kambe, E. Morii, T. Nakahata, A. Itai and H. Matsuda, *Blood*, 2005, **105**, 2324–2331.
- A. Tanaka, S. Muto, M. Konno, A. Itai and H. Matsuda, *Cancer Res.*, 2006, **66**, 419–426.
- N. A. Meanwell, *J. Med. Chem.*, 2011, **54**, 2529–2591.
- S. Sainas, A. C. Pippione, M. Giorgis, E. Lupino, P. Goyal, C. Ramondetti, B. Buccinna, M. Piccinini, R. C. Braga, C. H. Andrade, M. Andersson, A. C. Moritzer, R. Friemann, S. Mensa, S. Al-Kadaraghi, D. Boschi and M. L. Lolli, *Eur. J. Med. Chem.*, 2017, **129**, 287–302.
- M. Lolli, S. Narramore, C. W. Fishwick and K. Pors, *Drug Discovery Today*, 2015, **20**, 1018–1026.
- A. C. Pippione, F. Dosio, A. Ducime, A. Federico, K. Martina, S. Sainas, B. Frolund, M. Gooyit, K. D. Janda, D. Boschi and M. L. Lolli, *MedChemComm*, 2015, **6**, 1285–1292.
- D. Lehmann, R. Eckardt, G. Faust, W. Fiedler, W. Poepel, H. J. Jaensch, H. J. Heidrich and D. Lohmann, P, in, VEB Arzneimittelwerk, Ger. Dem. Rep., DD263767A1, 1989.
- t. H. Obtained from Sigma (code: I3159).
- t. H. Obtained from Sigma (code: P6624).
- A. Lennikov, M. Hiraoka, A. Abe, S. Ohno, T. Fujikawa, A. Itai and H. Ohguro, *Invest. Ophthalmol. Visual Sci.*, 2014, **55**, 6365–6373.

- 38 A. Sugita, H. Ogawa, M. Azuma, S. Muto, A. Honjo, H. Yanagawa, Y. Nishioka, K. Tani, A. Itai and S. Sone, *Int. Arch. Allergy Immunol.*, 2009, **148**, 186–198.
- 39 A. Gomez-Cabrero, W. Wrasidlo and R. A. Reisfeld, *PLoS One*, 2013, **8**, e73607.
- 40 N. Yamaguchi, T. Ito, S. Azuma, E. Ito, R. Honma, Y. Yanagisawa, A. Nishikawa, M. Kawamura, J. Imai, S. Watanabe, K. Semba and J. Inoue, *Cancer Sci.*, 2009, **100**, 1668–1674.
- 41 O. Sharif, V. N. Bolshakov, S. Raines, P. Newham and N. D. Perkins, *BMC Immunol.*, 2007, **8**, 1.